{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:17:50Z","timestamp":1790957870796,"version":"4.1.0"},"reference-count":127,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":536,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T00:00:00Z","timestamp":1589587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T00:00:00Z","timestamp":1589587200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Adoptive cell therapy (ACT) is an approach to cancer treatment that involves the use of antitumor immune cells to target residual disease in patients after completion of chemo\/radiotherapy. ACT has several advantages compared with other approaches in cancer immunotherapy, including the ability to specifically expand effector cells in vitro before selection for adoptive transfer, as well as the opportunity for host manipulation in order to enhance the ability of transferred cells to recognize and kill established tumors. One of the main challenges to the success of ACT in cancer clinical trials is the identification and generation of antitumor effector cells with high avidity for tumor recognition. Natural killer (NK) cells, cytokine-induced killers and natural killer T cells are key innate or innate-like effector cells in cancer immunosurveillance that act at the interface between innate and adaptive immunity, to have a greater influence over immune responses to cancer. In this review, we discuss recent studies that highlight their potential in cancer therapy and summarize clinical trials using these effector immune cells in adoptive cellular therapy for the treatment of cancer.<\/jats:p>\n               <jats:sec>\n                  <jats:title\/>\n               <\/jats:sec>","DOI":"10.1002\/sctm.19-0423","type":"journal-article","created":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T20:18:30Z","timestamp":1589660310000},"page":"974-984","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer"],"prefix":"10.1093","volume":"9","author":[{"given":"May","family":"Sabry","sequence":"first","affiliation":[{"name":"Department of Haematology University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Lowdell","sequence":"additional","affiliation":[{"name":"Department of Haematology University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,16]]},"reference":[{"issue":"25","key":"2022022809325468300_sct312715-bib-0001","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med"},{"issue":"5594","key":"2022022809325468300_sct312715-bib-0002","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with anti-tumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"issue":"10","key":"2022022809325468300_sct312715-bib-0003","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6382","key":"2022022809325468300_sct312715-bib-0004","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"6","key":"2022022809325468300_sct312715-bib-0005","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving CAR T-cells forward","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"2022022809325468300_sct312715-bib-0006","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nri3389","article-title":"Shades of grey\u2014the blurring view of innate and adaptive immunity","volume":"13","author":"Lanier","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2022022809325468300_sct312715-bib-0007","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nri3365","article-title":"Innate lymphoid cells\u2014a proposal for uniform nomenclature","volume":"13","author":"Spits","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"6055","key":"2022022809325468300_sct312715-bib-0008","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/319675a0","article-title":"Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy","volume":"319","author":"Karre","year":"1986","journal-title":"Nature"},{"issue":"5","key":"2022022809325468300_sct312715-bib-0009","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nri1603","article-title":"A new self: MHC-class-I-independent natural-killer-cell self-tolerance","volume":"5","author":"Kumar","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2022022809325468300_sct312715-bib-0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/cmi.2016.26","article-title":"NK cell education via nonclassical MHC and non-MHC ligands","volume":"14","author":"He","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"2022022809325468300_sct312715-bib-0011","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1034\/j.1600-065X.2001.1810113.x","article-title":"Ligands for natural killer cell receptors: redundancy or specificity","volume":"181","author":"Cerwenka","year":"2001","journal-title":"Immunol Rev"},{"key":"2022022809325468300_sct312715-bib-0012","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.smim.2017.08.002","article-title":"Natural killer cell-mediated immunosurveillance of human cancer","volume":"31","author":"Malmberg","year":"2017","journal-title":"Semin Immunol"},{"issue":"13","key":"2022022809325468300_sct312715-bib-0013","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood-2009-01-201632","article-title":"Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors","volume":"114","author":"Bryceson","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2022022809325468300_sct312715-bib-0014","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00262-016-1792-y","article-title":"Selection and expansion of natural killer cells for NK cell-based immunotherapy","volume":"65","author":"Becker","year":"2016","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"2022022809325468300_sct312715-bib-0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/sj.bmt.1704086","article-title":"IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I\/II trial","volume":"32","author":"Burns","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"9\u201310","key":"2022022809325468300_sct312715-bib-0016","first-page":"769","article-title":"Treatment of pressure sores: rarely based on guidelines","volume":"98","author":"Krause","year":"2004","journal-title":"Z Arztl Fortbild Qualitatssich"},{"key":"2022022809325468300_sct312715-bib-0017","doi-asserted-by":"crossref","first-page":"383","DOI":"10.7150\/jca.2.383","article-title":"Bortezomib treatment to potentiate the anti-tumor immunity of ex-vivo expanded adoptively infused autologous natural killer cells","volume":"2","author":"Lundqvist","year":"2011","journal-title":"J Cancer"},{"issue":"6","key":"2022022809325468300_sct312715-bib-0018","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.bbmt.2014.03.007","article-title":"Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma","volume":"20","author":"Rueff","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022022809325468300_sct312715-bib-0019","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12967-015-0632-8","article-title":"Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer","volume":"13","author":"Sakamoto","year":"2015","journal-title":"J Transl Med"},{"issue":"19","key":"2022022809325468300_sct312715-bib-0020","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-11-1347","article-title":"Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression","volume":"17","author":"Parkhurst","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2022022809325468300_sct312715-bib-0021","article-title":"Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma","volume":"5","author":"Leivas","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"5562","key":"2022022809325468300_sct312715-bib-0022","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"issue":"6","key":"2022022809325468300_sct312715-bib-0023","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060769","article-title":"Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy","volume":"11","author":"Lupo","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"21","key":"2022022809325468300_sct312715-bib-0024","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","article-title":"NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects","volume":"115","author":"Olson","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2022022809325468300_sct312715-bib-0025","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.4049\/jimmunol.0902598","article-title":"NK cell regulation of CD4 T cell-mediated graft-versus-host disease","volume":"184","author":"Noval Rivas","year":"2010","journal-title":"J Immunol"},{"issue":"9","key":"2022022809325468300_sct312715-bib-0026","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1172\/JCI1268","article-title":"Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation","volume":"101","author":"Asai","year":"1998","journal-title":"J Clin Invest"},{"issue":"8","key":"2022022809325468300_sct312715-bib-0027","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/00007890-199510000-00011","article-title":"The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells","volume":"60","author":"Xun","year":"1995","journal-title":"Transplantation"},{"issue":"2","key":"2022022809325468300_sct312715-bib-0028","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00007890-199308000-00031","article-title":"Acute graft-versus-host-like disease induced by transplantation of human activated natural killer cells into SCID mice","volume":"56","author":"Xun","year":"1993","journal-title":"Transplantation"},{"issue":"13","key":"2022022809325468300_sct312715-bib-0029","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1182\/blood-2005-04-1644","article-title":"KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation","volume":"106","author":"Cooley","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2022022809325468300_sct312715-bib-0030","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2014-07-592881","article-title":"Acute GVHD in patients receiving IL-15\/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation","volume":"125","author":"Shah","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2022022809325468300_sct312715-bib-0031","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2022022809325468300_sct312715-bib-0032","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/CJI.0000000000000059","article-title":"Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients","volume":"38","author":"Szmania","year":"2015","journal-title":"J Immunother"},{"issue":"12","key":"2022022809325468300_sct312715-bib-0033","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood-2011-01-329508","article-title":"Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients","volume":"118","author":"Curti","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2022022809325468300_sct312715-bib-0034","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/bmt.2012.162","article-title":"Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers","volume":"48","author":"Stern","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2022022809325468300_sct312715-bib-0035","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"2022022809325468300_sct312715-bib-0036","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/sj.leu.2403524","article-title":"Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation","volume":"18","author":"Passweg","year":"2004","journal-title":"Leukemia"},{"issue":"3","key":"2022022809325468300_sct312715-bib-0037","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bcmd.2004.08.013","article-title":"IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation","volume":"33","author":"Koehl","year":"2004","journal-title":"Blood Cells Mol Dis"},{"issue":"25","key":"2022022809325468300_sct312715-bib-0038","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","article-title":"Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein","volume":"123","author":"Bachanova","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2022022809325468300_sct312715-bib-0039","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s00262-010-0896-z","article-title":"Allogeneic natural killer cells for refractory lymphoma","volume":"59","author":"Bachanova","year":"2010","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"2022022809325468300_sct312715-bib-0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1158\/2326-6066.CIR-15-0118","article-title":"Phase I study of random healthy donor-derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors","volume":"4","author":"Yang","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"2022022809325468300_sct312715-bib-0041","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1007\/s12026-017-8927-x","article-title":"Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer","volume":"65","author":"Lin","year":"2017","journal-title":"Immunol Res"},{"issue":"5","key":"2022022809325468300_sct312715-bib-0042","article-title":"In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: a phase I clinical trial","volume":"7","author":"Adotevi","year":"2018","journal-title":"Onco Targets Ther"},{"key":"2022022809325468300_sct312715-bib-0043","author":"Cologne2014","year":"2014"},{"issue":"7","key":"2022022809325468300_sct312715-bib-0044","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbmt.2016.04.009","article-title":"Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: a Phase I trial","volume":"22","author":"Lee","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2022022809325468300_sct312715-bib-0045","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbmt.2015.12.028","article-title":"Phase II study of Haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation","volume":"22","author":"Shaffer","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022022809325468300_sct312715-bib-0046","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2018.02.033","article-title":"Haploidentical IL-15\/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia","volume":"422","author":"Vela","year":"2018","journal-title":"Cancer Lett"},{"issue":"13","key":"2022022809325468300_sct312715-bib-0047","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","article-title":"First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia","volume":"3","author":"Cooley","year":"2019","journal-title":"Blood Adv"},{"issue":"8","key":"2022022809325468300_sct312715-bib-0048","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.bbmt.2018.03.019","article-title":"A Phase 1 trial of CNDO-109-activated natural killer cells in patients with high-risk acute myeloid leukemia","volume":"24","author":"Fehniger","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2022022809325468300_sct312715-bib-0049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123416","article-title":"Two-stage priming of allogeneic natural killer cells for the treatment of patients with acute myeloid leukemia: a Phase I trial","volume":"10","author":"Kottaridis","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"2022022809325468300_sct312715-bib-0050","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1182\/blood-2002-04-1197","article-title":"Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor","volume":"100","author":"Davies","year":"2002","journal-title":"Blood"},{"key":"2022022809325468300_sct312715-bib-0051","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3389\/fimmu.2017.00631","article-title":"The rise of allogeneic natural killer cells as a platform for cancer immunotherapy: recent innovations and future developments","volume":"8","author":"Veluchamy","year":"2017","journal-title":"Front Immunol"},{"issue":"6","key":"2022022809325468300_sct312715-bib-0052","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14653240802301872","article-title":"Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial","volume":"10","author":"Arai","year":"2008","journal-title":"Cytotherapy"},{"issue":"12","key":"2022022809325468300_sct312715-bib-0053","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","article-title":"Treatment of patients with advanced cancer with the natural killer cell line NK-92","volume":"15","author":"Tonn","year":"2013","journal-title":"Cytotherapy"},{"issue":"6","key":"2022022809325468300_sct312715-bib-0054","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/14737159.2016.1174578","article-title":"Plasma-derived exosomes in acute myeloid leukemia for detection of minimal residual disease: are we ready?","volume":"16","author":"Boyiadzis","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"issue":"51","key":"2022022809325468300_sct312715-bib-0055","doi-asserted-by":"crossref","first-page":"89256","DOI":"10.18632\/oncotarget.19204","article-title":"A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy","volume":"8","author":"Williams","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"2022022809325468300_sct312715-bib-0056","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jcyt.2017.07.008","article-title":"Phase 1 clinical trial of adoptive immunotherapy using \"off-the-shelf\" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia","volume":"19","author":"Boyiadzis","year":"2017","journal-title":"Cytotherapy"},{"issue":"3","key":"2022022809325468300_sct312715-bib-0057","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br J Haematol"},{"issue":"13","key":"2022022809325468300_sct312715-bib-0058","first-page":"1673","article-title":"Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells","volume":"21","author":"Schmidt-Wolf","year":"1993","journal-title":"Exp Hematol"},{"issue":"21","key":"2022022809325468300_sct312715-bib-0059","first-page":"6178","article-title":"Major histocompatibility complex class I-related chain a and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity","volume":"62","author":"Pende","year":"2002","journal-title":"Cancer Res"},{"issue":"4","key":"2022022809325468300_sct312715-bib-0060","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/hon.2326","article-title":"Increase of CIK cell efficacy by upregulating cell surface MICA and inhibition of NKG2D ligand shedding in multiple myeloma","volume":"35","author":"Nwangwu","year":"2017","journal-title":"Hematol Oncol"},{"issue":"6","key":"2022022809325468300_sct312715-bib-0061","first-page":"1380","article-title":"Roles of NKG2D in cytokine-induced killer (CIK) against hematological malignant cells lines","volume":"21","author":"He","year":"2013","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"2022022809325468300_sct312715-bib-0062","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3389\/fimmu.2017.00774","article-title":"Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy","volume":"8","author":"Gao","year":"2017","journal-title":"Front Immunol"},{"key":"2022022809325468300_sct312715-bib-0063","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fonc.2012.00032","article-title":"Cytotoxic capacity of IL-15-stimulated cytokine-induced killer cells against human acute myeloid leukemia and Rhabdomyosarcoma in humanized preclinical mouse models","volume":"2","author":"Rettinger","year":"2012","journal-title":"Front Oncol"},{"key":"2022022809325468300_sct312715-bib-0064","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3389\/fimmu.2019.01218","article-title":"Improving clinical manufacturing of IL-15 activated cytokine-induced killer (CIK) cells","volume":"10","author":"Bremm","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"2022022809325468300_sct312715-bib-0065","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2141.1994.tb08297.x","article-title":"Propagation of large numbers of T cells with natural killer cell markers","volume":"87","author":"Schmidt-Wolf","year":"1994","journal-title":"Br J Haematol"},{"issue":"6","key":"2022022809325468300_sct312715-bib-0066","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.bjc.6690800","article-title":"Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma","volume":"81","author":"Schmidt-Wolf","year":"1999","journal-title":"Br J Cancer"},{"issue":"17","key":"2022022809325468300_sct312715-bib-0067","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1158\/1078-0432.CCR-17-0492","article-title":"Dendritic cell\/cytokine-induced killer cell immunotherapy combined with S-1 in patients with advanced pancreatic cancer: a prospective study","volume":"23","author":"Jiang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2022022809325468300_sct312715-bib-0068","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1078-0432.CCR-18-2360","article-title":"Autologous dendritic cell-cytokine induced killer cell immunotherapy combined with S-1 plus Cisplatin in patients with advanced gastric cancer: a prospective study","volume":"25","author":"Qiao","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2022022809325468300_sct312715-bib-0069","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.2147\/DDDT.S146959","article-title":"Adjuvant immunotherapy of dendritic cells and cytokine-induced killer cells is safe and enhances chemotherapy efficacy for multiple myeloma in China: a meta-analysis of clinical trials","volume":"11","author":"Wang","year":"2017","journal-title":"Drug des Devel Ther"},{"issue":"1","key":"2022022809325468300_sct312715-bib-0070","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12094-015-1339-2","article-title":"Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged &lt;45)","volume":"18","author":"Wang","year":"2016","journal-title":"Clin Transl Oncol"},{"issue":"1\u20132","key":"2022022809325468300_sct312715-bib-0071","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000452531","article-title":"Phase II\/III study of radiofrequency ablation combined with cytokine-induced killer cells treating colorectal liver metastases","volume":"40","author":"Li","year":"2016","journal-title":"Cell Physiol Biochem"},{"issue":"3","key":"2022022809325468300_sct312715-bib-0072","article-title":"A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma","volume":"5","author":"Xu","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"7","key":"2022022809325468300_sct312715-bib-0073","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2015.02.055","article-title":"Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma","volume":"148","author":"Lee","year":"2015","journal-title":"Gastroenterology"},{"issue":"7","key":"2022022809325468300_sct312715-bib-0074","doi-asserted-by":"crossref","first-page":"P1293","DOI":"10.1016\/j.bbmt.2019.03.027","article-title":"Donor-derived cytokine-induced killer cell infusion as consolidation after nonmyeloablative allogeneic transplantation for myeloid neoplasms","volume":"25","author":"Narayan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2022022809325468300_sct312715-bib-0075","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3324\/haematol.11132","article-title":"Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study","volume":"92","author":"Introna","year":"2007","journal-title":"Haematologica"},{"issue":"11","key":"2022022809325468300_sct312715-bib-0076","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.bbmt.2010.05.015","article-title":"Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation","volume":"16","author":"Introna","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2022022809325468300_sct312715-bib-0077","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1172\/JCI200423594","article-title":"Going both ways: immune regulation via CD1d-dependent NKT cells","volume":"114","author":"Godfrey","year":"2004","journal-title":"J Clin Invest"},{"issue":"5343","key":"2022022809325468300_sct312715-bib-0078","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1126\/science.278.5343.1626","article-title":"CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides","volume":"278","author":"Kawano","year":"1997","journal-title":"Science"},{"issue":"32","key":"2022022809325468300_sct312715-bib-0079","doi-asserted-by":"crossref","first-page":"11287","DOI":"10.1073\/pnas.0801631105","article-title":"Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population","volume":"105","author":"Coquet","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2022022809325468300_sct312715-bib-0080","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s12272-019-01139-8","article-title":"Roles of NKT cells in cancer immunotherapy","volume":"42","author":"Bae","year":"2019","journal-title":"Arch Pharm Res"},{"issue":"7","key":"2022022809325468300_sct312715-bib-0081","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.4049\/jimmunol.167.7.4046","article-title":"Loss of IFN-gamma production by invariant NK T cells in advanced cancer","volume":"167","author":"Tahir","year":"2001","journal-title":"J Immunol"},{"issue":"12","key":"2022022809325468300_sct312715-bib-0082","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.4049\/jimmunol.168.12.6494","article-title":"Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide","volume":"168","author":"Yanagisawa","year":"2002","journal-title":"J Immunol"},{"issue":"4","key":"2022022809325468300_sct312715-bib-0083","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1365-2141.2003.04465.x","article-title":"Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes","volume":"122","author":"Fujii","year":"2003","journal-title":"Br J Haematol"},{"issue":"1","key":"2022022809325468300_sct312715-bib-0084","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ijc.20998","article-title":"Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load","volume":"116","author":"Molling","year":"2005","journal-title":"Int J Cancer"},{"issue":"2","key":"2022022809325468300_sct312715-bib-0085","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clim.2011.04.017","article-title":"Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects","volume":"140","author":"Exley","year":"2011","journal-title":"Clin Immunol"},{"issue":"2","key":"2022022809325468300_sct312715-bib-0086","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.clim.2010.11.010","article-title":"Clinical experience with alpha-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B\/C infection","volume":"140","author":"Schneiders","year":"2011","journal-title":"Clin Immunol"},{"issue":"7","key":"2022022809325468300_sct312715-bib-0087","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1200\/JCO.2006.08.5787","article-title":"Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma","volume":"25","author":"Molling","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"2022022809325468300_sct312715-bib-0088","first-page":"3702","article-title":"A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors","volume":"8","author":"Giaccone","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2022022809325468300_sct312715-bib-0089","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2003-04-1155","article-title":"Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity","volume":"103","author":"Nieda","year":"2004","journal-title":"Blood"},{"issue":"9","key":"2022022809325468300_sct312715-bib-0090","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1084\/jem.20042592","article-title":"Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients","volume":"201","author":"Chang","year":"2005","journal-title":"J Exp Med"},{"issue":"5","key":"2022022809325468300_sct312715-bib-0091","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10875-012-9697-9","article-title":"Accumulation of activated invariant natural killer T cells in the tumor microenvironment after alpha-galactosylceramide-pulsed antigen presenting cells","volume":"32","author":"Nagato","year":"2012","journal-title":"J Clin Immunol"},{"issue":"4","key":"2022022809325468300_sct312715-bib-0092","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.4049\/jimmunol.0800126","article-title":"A phase I-II study of alpha-galactosylceramide-pulsed IL-2\/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer","volume":"182","author":"Motohashi","year":"2009","journal-title":"J Immunol"},{"issue":"14","key":"2022022809325468300_sct312715-bib-0093","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1158\/1078-0432.CCR-16-0600","article-title":"Adoptive transfer of invariant NKT cells as immunotherapy for advanced melanoma: a Phase I clinical trial","volume":"23","author":"Exley","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2022022809325468300_sct312715-bib-0094","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.clim.2010.11.014","article-title":"Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy","volume":"138","author":"Yamasaki","year":"2011","journal-title":"Clin Immunol"},{"issue":"7","key":"2022022809325468300_sct312715-bib-0095","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1172\/JCI42027","article-title":"Murine induced pluripotent stem cells can be derived from and differentiate into natural killer T cells","volume":"120","author":"Watarai","year":"2010","journal-title":"J Clin Invest"},{"issue":"2","key":"2022022809325468300_sct312715-bib-0096","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent anti-tumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"2022022809325468300_sct312715-bib-0097","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jcyt.2016.10.009","article-title":"Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma","volume":"19","author":"Oelsner","year":"2017","journal-title":"Cytotherapy"},{"issue":"9","key":"2022022809325468300_sct312715-bib-0098","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.21873\/anticanres.12824","article-title":"Novel human NK cell line carrying CAR targeting EGFRvIII induces anti-tumor effects in Glioblastoma cells","volume":"38","author":"Murakami","year":"2018","journal-title":"Anticancer Res"},{"issue":"5","key":"2022022809325468300_sct312715-bib-0099","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/CJI.0000000000000082","article-title":"Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12\/SDF-1alpha-secreting Glioblastoma","volume":"38","author":"Muller","year":"2015","journal-title":"J Immunother"},{"issue":"3","key":"2022022809325468300_sct312715-bib-0100","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1582-4934.2011.01343.x","article-title":"NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin","volume":"16","author":"Esser","year":"2012","journal-title":"J Cell Mol Med"},{"issue":"3","key":"2022022809325468300_sct312715-bib-0101","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00262-007-0383-3","article-title":"Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells","volume":"57","author":"Muller","year":"2008","journal-title":"Cancer Immunol Immunother"},{"issue":"45","key":"2022022809325468300_sct312715-bib-0102","doi-asserted-by":"crossref","first-page":"17481","DOI":"10.1073\/pnas.0804788105","article-title":"Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas","volume":"105","author":"Kruschinski","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2022022809325468300_sct312715-bib-0103","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2022022809325468300_sct312715-bib-0104","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1158\/2326-6066.CIR-14-0114","article-title":"Targeting CD20+ aggressive B-cell non-Hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice","volume":"3","author":"Chu","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"15","key":"2022022809325468300_sct312715-bib-0105","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1158\/1078-0432.CCR-08-2810","article-title":"2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells","volume":"15","author":"Altvater","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2022022809325468300_sct312715-bib-0106","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3389\/fimmu.2018.00153","article-title":"Current status of gene engineering cell therapeutics","volume":"9","author":"Saudemont","year":"2018","journal-title":"Front Immunol"},{"key":"2022022809325468300_sct312715-bib-0107","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fphar.2015.00021","article-title":"Advantages and applications of CAR-expressing natural killer cells","volume":"6","author":"Glienke","year":"2015","journal-title":"Front Pharmacol"},{"key":"2022022809325468300_sct312715-bib-0108","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105695","article-title":"Chimeric antigen receptor (CAR)-modified NK cells against cancer: opportunities and challenges","volume":"74","author":"Wang","year":"2019","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"2022022809325468300_sct312715-bib-0109","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1182\/blood.V91.10.3850","article-title":"Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo","volume":"91","author":"Nagashima","year":"1998","journal-title":"Blood"},{"issue":"3","key":"2022022809325468300_sct312715-bib-0110","first-page":"338","article-title":"Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy","volume":"89","author":"Zhang","year":"2004","journal-title":"Haematologica"},{"issue":"3","key":"2022022809325468300_sct312715-bib-0111","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/14653240801965156","article-title":"Functional characterization of interleukin-15 gene transduction into the human natural killer cell line NKL","volume":"10","author":"Jiang","year":"2008","journal-title":"Cytotherapy"},{"issue":"8","key":"2022022809325468300_sct312715-bib-0112","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1089\/10430349950018030","article-title":"Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy","volume":"10","author":"Tam","year":"1999","journal-title":"Hum Gene Ther"},{"issue":"2","key":"2022022809325468300_sct312715-bib-0113","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.exphem.2004.11.003","article-title":"Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells","volume":"33","author":"Konstantinidis","year":"2005","journal-title":"Exp Hematol"},{"issue":"5","key":"2022022809325468300_sct312715-bib-0114","first-page":"1097","article-title":"Characterization of stem cell factor gene-modified human natural killer cell line, NK-92 cells: implication in NK cell-based adoptive cellular immunotherapy","volume":"11","author":"Zhang","year":"2004","journal-title":"Oncol Rep"},{"issue":"1","key":"2022022809325468300_sct312715-bib-0115","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000495771","article-title":"CAR-expressing natural killer cells for cancer retargeting","volume":"46","author":"Kloess","year":"2019","journal-title":"Transfus Med Hemother"},{"key":"2022022809325468300_sct312715-bib-0116","article-title":"Are natural killer cells superior CAR drivers?","volume":"3","author":"Klingemann","year":"2014","journal-title":"Onco Targets Ther"},{"issue":"7","key":"2022022809325468300_sct312715-bib-0117","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/jcmm.12810","article-title":"CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies","volume":"20","author":"Romanski","year":"2016","journal-title":"J Cell Mol Med"},{"key":"2022022809325468300_sct312715-bib-0118","doi-asserted-by":"crossref","first-page":"11483","DOI":"10.1038\/srep11483","article-title":"CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells","volume":"5","author":"Han","year":"2015","journal-title":"Sci Rep"},{"issue":"5","key":"2022022809325468300_sct312715-bib-0119","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv375","article-title":"ErbB2\/HER2-specific NK cells for targeted therapy of glioblastoma","volume":"108","author":"Zhang","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2022022809325468300_sct312715-bib-0120","article-title":"Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances anti-tumor activity and survival","volume":"5","author":"Genssler","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"3","key":"2022022809325468300_sct312715-bib-0121","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bjh.12282","article-title":"Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor","volume":"161","author":"Tettamanti","year":"2013","journal-title":"Br J Haematol"},{"key":"2022022809325468300_sct312715-bib-0122","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/238924","article-title":"Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells","volume":"2012","author":"Schlimper","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"12","key":"2022022809325468300_sct312715-bib-0123","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00262-015-1757-6","article-title":"Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances anti-tumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies","volume":"64","author":"Ren","year":"2015","journal-title":"Cancer Immunol Immunother"},{"issue":"39","key":"2022022809325468300_sct312715-bib-0124","doi-asserted-by":"crossref","first-page":"66137","DOI":"10.18632\/oncotarget.19821","article-title":"Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children","volume":"8","author":"Merker","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"2022022809325468300_sct312715-bib-0125","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/mt.2013.192","article-title":"Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 \"super-stimulation\"","volume":"21","author":"Hombach","year":"2013","journal-title":"Mol Ther"},{"issue":"5","key":"2022022809325468300_sct312715-bib-0126","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1089\/hum.2017.207","article-title":"Preclinical efficacy and safety of CD19CAR cytokine-induced killer cells transfected with sleeping beauty transposon for the treatment of acute lymphoblastic leukemia","volume":"29","author":"Magnani","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"6","key":"2022022809325468300_sct312715-bib-0127","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/ejh.13170","article-title":"NKT cells\u2014new players in CAR cell immunotherapy?","volume":"101","author":"Kriegsmann","year":"2018","journal-title":"Eur J Haematol"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fsctm.19-0423","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/sctm.19-0423","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/sctm.19-0423","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/9\/9\/974\/42628988\/stcltm_9_9_974.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/9\/9\/974\/42628988\/stcltm_9_9_974.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T09:44:22Z","timestamp":1646041462000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/9\/9\/974\/6406909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,16]]},"references-count":127,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,5,16]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1002\/sctm.19-0423","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9,1]]},"published":{"date-parts":[[2020,5,16]]},"assertion":[{"value":"2019-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}